Search

everythinglearnresearchcommunity

for

Search:↓

Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

The combination treatment showed a higher response rate but no significant survival benefits.

Ocoxin improves quality of life for advanced ovarian cancer patients on chemotherapy.

Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

The combination of encorafenib and binimetinib caused few skin issues.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.

Promising cancer treatments were found, but the manufacturer closed.

Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

Ocrelizumab may cause pancreatitis in some patients.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.

Ocrelizumab helped control lupus in a pregnant patient, leading to the birth of a healthy baby.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

Suppressing ODC activity reduces tumor growth in hair follicles.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.

The treatment improved survival and controlled cancer spread but required managing side effects like rashes.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Anti-CD19 therapy may help treat SLE and NMOSD.

Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.

Oral minoxidil can help regrow hair lost from antibody-drug conjugate treatment.